Search results
Showing 1 to 15 of 38 results for tocilizumab
This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.
Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)
Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.
Our health inequalities guidance supports strategies that improve population health as a whole, while offering particular benefit to the most disadvantaged
Supporting the health and care system in improving productivity
Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.
1.4 million more people at risk of severe COVID-19 to have access to antiviral Paxlovid
A further 1.4 million people who have an increased risk for progression to severe COVID-19 will be eligible for Paxlovid if they test positive following updated NICE final draft guidance published today (11 January 2024).
etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review [ID537] 26 November 2015 TA141 Rheumatoid...
Evidence-based recommendations on tixagevimab plus cilgavimab (Evusheld) for preventing COVID-19 in adults.
NICE recommends 3 treatments for COVID-19 in final draft guidance
Everyone with COVID-19 at highest risk of developing severe disease will have access to clinically and cost-effective treatments, under final draft guidance published by NICE today.
Dr Ravinder Claire outlines recent progress towards greater use of real-world evidence in regulatory decision-making. He also considers the implications and opportunities for NICE and our stakeholders.
Three treatments for COVID have been recommended in draft NICE guidance released today for public consultation.
The NICE real-world evidence framework aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence
Show all sections
- Overview
- Introduction to real-world evidence in NICE decision making
- Conduct of quantitative real-world evidence studies
- Assessing data suitability
- Methods for real-world studies of comparative effects
- Appendix 1 - Data Suitability Assessment Tool (DataSAT)
- Appendix 2 - Reporting on methods used to minimise risk of bias
- Appendix 3 - Reporting information for selected analytical methods
Evidence-based recommendations on selumetinib (Koselugo) for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over.
Tofacitinib for treating juvenile idiopathic arthritis (TA735)
Evidence-based recommendations on tofacitinib for treating juvenile idiopathic arthritis.
Evidence-based recommendations on adalimumab, etanercept, infliximab and abatacept for adults with moderate rheumatoid arthritis who have tried conventional DMARDs but they have not worked.
Evidence-based recommendations on anakinra (Kineret) for treating adult-onset Still’s disease and systemic juvenile idiopathic arthritis in people 8 months and older.